GTHX Total Current Liabilities vs Net Debt Analysis

GTHX Stock

USD 4.40 0.13 2.87%

G1 Therapeutics financial indicator trend analysis is much more than just examining G1 Therapeutics latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether G1 Therapeutics is a good investment. Please check the relationship between G1 Therapeutics Total Current Liabilities and its Net Debt accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in G1 Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate.

For more information on how to buy GTHX Stock please use our How to Invest in G1 Therapeutics guide.

Total Current Liabilities vs Net Debt

Total Current Liabilities vs Net Debt Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of G1 Therapeutics Total Current Liabilities account and Net Debt. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between G1 Therapeutics' Total Current Liabilities and Net Debt is -0.23. Overlapping area represents the amount of variation of Total Current Liabilities that can explain the historical movement of Net Debt in the same time period over historical financial statements of G1 Therapeutics, assuming nothing else is changed. The correlation between historical values of G1 Therapeutics' Total Current Liabilities and Net Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Current Liabilities of G1 Therapeutics are associated (or correlated) with its Net Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Debt has no effect on the direction of Total Current Liabilities i.e., G1 Therapeutics' Total Current Liabilities and Net Debt go up and down completely randomly.

Correlation Coefficient

-0.23

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Total Current Liabilities

Total Current Liabilities is an item on G1 Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of G1 Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Net Debt

The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.

Most indicators from G1 Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into G1 Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in G1 Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate.

For more information on how to buy GTHX Stock please use our How to Invest in G1 Therapeutics guide.Selling General Administrative is likely to drop to about 46.9 M in 2024. Tax Provision is likely to drop to about 1.9 M in 2024

G1 Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Shares Outstanding	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Property Plant Equipment	Common Stock Total Equity	Property Plant And Equipment Gross	Treasury Stock	Other Liab	Retained Earnings Total Equity	Capital Surpluse
Total Assets		0.61	0.7	-0.66	0.95	0.69	-0.81	-0.59	0.67	0.93	0.69	0.79	0.99	0.78	0.53	0.17	0.52	1.0	0.8	0.55	0.81	0.68	0.06	0.59	-0.54	0.72
Other Current Liab	0.61		0.92	-0.27	0.44	0.69	-0.14	-0.88	0.8	0.38	0.67	0.3	0.52	0.85	0.74	0.66	0.92	0.6	0.86	0.41	0.86	0.77	0.45	0.82	-0.88	0.89
Total Current Liabilities	0.7	0.92		-0.4	0.53	0.82	-0.23	-0.93	0.88	0.47	0.82	0.48	0.61	0.93	0.85	0.63	0.94	0.68	0.94	0.42	0.94	0.88	0.41	0.92	-0.93	0.94
Total Stockholder Equity	-0.66	-0.27	-0.4		-0.61	-0.66	0.66	0.26	-0.12	-0.73	-0.69	-0.78	-0.66	-0.43	-0.61	0.37	-0.37	-0.65	-0.39	-0.44	-0.39	-0.6	0.22	-0.52	0.27	-0.41
Net Tangible Assets	0.95	0.44	0.53	-0.61		0.58	-0.86	-0.43	0.5	0.92	0.57	0.71	0.96	0.61	0.34	0.07	0.31	0.95	0.72	0.56	0.72	0.55	0.06	0.45	-0.36	0.59
Property Plant And Equipment Net	0.69	0.69	0.82	-0.66	0.58		-0.37	-0.73	0.62	0.55	1.0	0.48	0.63	0.78	0.72	0.29	0.71	0.67	0.76	0.77	0.76	0.99	0.2	0.93	-0.74	0.78
Net Debt	-0.81	-0.14	-0.23	0.66	-0.86	-0.37		0.02	-0.28	-0.96	-0.37	-0.8	-0.86	-0.37	-0.1	0.38	-0.02	-0.82	-0.4	-0.47	-0.41	-0.3	0.33	-0.16	-0.03	-0.24
Retained Earnings	-0.59	-0.88	-0.93	0.26	-0.43	-0.73	0.02		-0.78	-0.28	-0.73	-0.28	-0.5	-0.88	-0.81	-0.8	-0.9	-0.58	-0.87	-0.34	-0.88	-0.81	-0.63	-0.87	0.99	-0.95
Accounts Payable	0.67	0.8	0.88	-0.12	0.5	0.62	-0.28	-0.78		0.46	0.61	0.43	0.6	0.83	0.56	0.65	0.75	0.66	0.84	0.36	0.85	0.67	0.25	0.68	-0.75	0.75
Cash	0.93	0.38	0.47	-0.73	0.92	0.55	-0.96	-0.28	0.46		0.55	0.86	0.95	0.57	0.35	-0.19	0.28	0.93	0.6	0.51	0.6	0.5	-0.21	0.38	-0.23	0.47
Non Current Assets Total	0.69	0.67	0.82	-0.69	0.57	1.0	-0.37	-0.73	0.61	0.55		0.51	0.63	0.77	0.76	0.27	0.72	0.67	0.75	0.74	0.76	0.99	0.18	0.93	-0.74	0.78
Non Currrent Assets Other	0.79	0.3	0.48	-0.78	0.71	0.48	-0.8	-0.28	0.43	0.86	0.51		0.8	0.58	0.56	-0.22	0.37	0.79	0.52	0.2	0.53	0.44	-0.24	0.37	-0.25	0.41
Cash And Short Term Investments	0.99	0.52	0.61	-0.66	0.96	0.63	-0.86	-0.5	0.6	0.95	0.63	0.8		0.71	0.44	0.09	0.42	1.0	0.73	0.54	0.74	0.6	0.0	0.5	-0.45	0.64
Common Stock Shares Outstanding	0.78	0.85	0.93	-0.43	0.61	0.78	-0.37	-0.88	0.83	0.57	0.77	0.58	0.71		0.77	0.56	0.81	0.77	0.91	0.47	0.92	0.82	0.47	0.85	-0.84	0.92
Other Current Assets	0.53	0.74	0.85	-0.61	0.34	0.72	-0.1	-0.81	0.56	0.35	0.76	0.56	0.44	0.77		0.39	0.91	0.51	0.72	0.17	0.72	0.78	0.32	0.85	-0.84	0.81
Other Stockholder Equity	0.17	0.66	0.63	0.37	0.07	0.29	0.38	-0.8	0.65	-0.19	0.27	-0.22	0.09	0.56	0.39		0.62	0.16	0.6	0.06	0.6	0.4	0.74	0.51	-0.78	0.65
Total Liab	0.52	0.92	0.94	-0.37	0.31	0.71	-0.02	-0.9	0.75	0.28	0.72	0.37	0.42	0.81	0.91	0.62		0.51	0.8	0.23	0.8	0.79	0.37	0.87	-0.94	0.89
Total Current Assets	1.0	0.6	0.68	-0.65	0.95	0.67	-0.82	-0.58	0.66	0.93	0.67	0.79	1.0	0.77	0.51	0.16	0.51		0.79	0.54	0.8	0.66	0.06	0.57	-0.53	0.71
Common Stock	0.8	0.86	0.94	-0.39	0.72	0.76	-0.4	-0.87	0.84	0.6	0.75	0.52	0.73	0.91	0.72	0.6	0.8	0.79		0.47	1.0	0.81	0.47	0.84	-0.83	0.93
Property Plant Equipment	0.55	0.41	0.42	-0.44	0.56	0.77	-0.47	-0.34	0.36	0.51	0.74	0.2	0.54	0.47	0.17	0.06	0.23	0.54	0.47		0.47	0.72	0.07	0.58	-0.31	0.42
Common Stock Total Equity	0.81	0.86	0.94	-0.39	0.72	0.76	-0.41	-0.88	0.85	0.6	0.76	0.53	0.74	0.92	0.72	0.6	0.8	0.8	1.0	0.47		0.81	0.47	0.84	-0.83	0.93
Property Plant And Equipment Gross	0.68	0.77	0.88	-0.6	0.55	0.99	-0.3	-0.81	0.67	0.5	0.99	0.44	0.6	0.82	0.78	0.4	0.79	0.66	0.81	0.72	0.81		0.3	0.97	-0.82	0.85
Treasury Stock	0.06	0.45	0.41	0.22	0.06	0.2	0.33	-0.63	0.25	-0.21	0.18	-0.24	0.0	0.47	0.32	0.74	0.37	0.06	0.47	0.07	0.47	0.3		0.44	-0.56	0.57
Other Liab	0.59	0.82	0.92	-0.52	0.45	0.93	-0.16	-0.87	0.68	0.38	0.93	0.37	0.5	0.85	0.85	0.51	0.87	0.57	0.84	0.58	0.84	0.97	0.44		-0.89	0.9
Retained Earnings Total Equity	-0.54	-0.88	-0.93	0.27	-0.36	-0.74	-0.03	0.99	-0.75	-0.23	-0.74	-0.25	-0.45	-0.84	-0.84	-0.78	-0.94	-0.53	-0.83	-0.31	-0.83	-0.82	-0.56	-0.89		-0.94
Capital Surpluse	0.72	0.89	0.94	-0.41	0.59	0.78	-0.24	-0.95	0.75	0.47	0.78	0.41	0.64	0.92	0.81	0.65	0.89	0.71	0.93	0.42	0.93	0.85	0.57	0.9	-0.94

Click cells to compare fundamentals

G1 Therapeutics Account Relationship Matchups

G1 Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	284.8M	228.6M	254.1M	188.0M	121.5M	179.2M
Other Current Liab	15.4M	3.1M	23.6M	27.0M	23.8M	12.5M
Total Current Liabilities	19.8M	23.4M	27.6M	35.6M	29.7M	18.5M
Total Stockholder Equity	(336.9M)	(436.1M)	(584.5M)	68.7M	35.4M	37.2M
Net Tangible Assets	255.5M	177.4M	143.5M	68.7M	79.1M	121.0M
Property Plant And Equipment Net	13.4M	10.5M	9.0M	8.0M	6.4M	5.4M
Net Debt	(259.0M)	(179.5M)	(138.1M)	(10.8M)	24.9M	26.1M
Retained Earnings	(336.9M)	(436.1M)	(584.5M)	(732.0M)	(780.0M)	(741.0M)
Accounts Payable	3.7M	3.6M	2.9M	7.4M	4.0M	3.6M
Cash	269.2M	207.3M	221.2M	94.6M	32.3M	30.7M
Non Current Assets Total	13.8M	12.2M	10.5M	8.5M	6.6M	5.9M
Non Currrent Assets Other	437K	1.2M	1.2M	264K	21K	20.0K
Cash And Short Term Investments	269.2M	207.3M	221.2M	145.1M	82.2M	161.9M
Common Stock Shares Outstanding	37.5M	37.9M	41.9M	43.6M	51.7M	33.7M
Other Current Assets	1.8M	8.8M	13.2M	7.1M	7.6M	4.6M
Other Stockholder Equity	222.7M	318K	(4K)	800.8M	815.4M	856.1M
Total Liab	29.3M	51.2M	110.6M	119.2M	86.2M	47.2M
Total Current Assets	271.0M	216.4M	243.6M	179.5M	114.9M	173.3M
Property Plant Equipment	13.4M	2.5M	2.0M	2.0M	2.3M	2.7M
Liabilities And Stockholders Equity	(307.5M)	(384.9M)	(473.9M)	188.0M	121.5M	127.6M
Property Plant And Equipment Gross	13.4M	10.5M	10.3M	9.8M	8.7M	6.7M
Non Current Liabilities Total	9.5M	27.8M	82.9M	83.6M	56.4M	35.8M
Non Current Liabilities Other	9.5M	7.9M	6.8M	5.6M	41K	39.0K
Retained Earnings Total Equity	(336.9M)	(436.1M)	(584.5M)	(732.0M)	(658.8M)	(625.9M)
Capital Surpluse	592.4M	613.5M	728.0M	800.8M	920.9M	647.2M
Net Invested Capital	255.5M	197.2M	218.7M	145.8M	86.9M	155.0M
Net Working Capital	251.2M	192.9M	216.0M	143.9M	85.2M	153.1M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

WD	Walker Dunlop
MSFT	Microsoft
BAC	Bank of America

When determining whether G1 Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of G1 Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of G1 Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on G1 Therapeutics Stock:

How To Invest In GTHX

Details

Is GTHX Stock a good investment?

Details

What is G1 Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in G1 Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate.

For more information on how to buy GTHX Stock please use our How to Invest in G1 Therapeutics guide.

Note that the G1 Therapeutics information on this page should be used as a complementary analysis to other G1 Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.

Complementary Tools for GTHX Stock analysis

When running G1 Therapeutics' price analysis, check to measure G1 Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy G1 Therapeutics is operating at the current time. Most of G1 Therapeutics' value examination focuses on studying past and present price action to predict the probability of G1 Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move G1 Therapeutics' price. Additionally, you may evaluate how the addition of G1 Therapeutics to your portfolios can decrease your overall portfolio volatility.

	ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
	Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
	Equity Valuation Check real value of public entities based on technical and fundamental data
	Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
	Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities
	Share Portfolio Track or share privately all of your investments from the convenience of any device
	Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments
	Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets
	Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk
	Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market.
	Economic Indicators Top statistical indicators that provide insights into how an economy is performing
	Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets

Is G1 Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of G1 Therapeutics. If investors know GTHX will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about G1 Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.60)

Revenue Per Share

1.62

Quarterly Revenue Growth

0.118

Return On Assets

(0.11)

Return On Equity

(0.84)

The market value of G1 Therapeutics is measured differently than its book value, which is the value of GTHX that is recorded on the company's balance sheet. Investors also form their own opinion of G1 Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is G1 Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because G1 Therapeutics' market value can be influenced by many factors that don't directly affect G1 Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between G1 Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if G1 Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, G1 Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

GTHX Total Current Liabilities vs Net Debt Analysis

Total Current Liabilities vs Net Debt

Total Current Liabilities vs Net Debt Correlation Analysis

Correlation Coefficient

Total Current Liabilities

Net Debt

G1 Therapeutics fundamental ratios Correlations

G1 Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

G1 Therapeutics fundamental ratios Accounts

Also Currently Popular

Complementary Tools for GTHX Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Non Current Assets Total	+ 1.0	Property Plant And Equipment Net
Total Current Assets	+ 1.0	Cash And Short Term Investments
Common Stock Total Equity	+ 1.0	Common Stock
Cash And Short Term Investments	+ 0.99	Total Assets
Property Plant And Equipment Gross	+ 0.99	Property Plant And Equipment Net

Cash	- 0.96	Net Debt
Capital Surpluse	- 0.95	Retained Earnings
Capital Surpluse	- 0.94	Retained Earnings Total Equity
Retained Earnings Total Equity	- 0.94	Total Liab
Retained Earnings Total Equity	- 0.93	Total Current Liabilities
Retained Earnings	- 0.93	Total Current Liabilities